References
- John VJ, McClintic JE, Hess DJ, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. OSLI Retina. 2016;47(1):14–19. doi:10.3928/23258160-20151214-02.
- Kashani AH, Brown KT, Chang E, Drenser KA, Capone A, Trese MT. Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy. Ophthalmology. 2014;121(11):2220–27. doi:10.1016/j.ophtha.2014.05.029.
- Darlow BA, Lui K, Kusuda S, Reichman B, Hakansson S, Bassler D, Modi N, Lee SK, Lehtonen L, Vento M, et al. International variation and trends in the treatment for retinopathy of prematurity. Br J Ophthalmol. 2017;101:1399–404.
- Carrion JZ, Filho JBF, Tartarella MB, Zin A, Jornada JID. Prevalence of retinopathy of prematurity in Latin America. Clin Ophthalmol. 2011;5:1687–95. doi:10.2147/OPTH.S25166.
- Lee JW, Mazara FS, Olivier A, McCabe F, Rivera L, Martin RN, Davis JM. Retinopathy of prematurity in the dominican republic: challenges to screening and prevention. Am J Perinatol. 2012;29:801–06. doi:10.1055/s-0032-1316441.
- Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018 Feb;125(2):218–26. doi:10.1016/j.ophtha.2017.08.005.